JAK2 and breast cancer: IL-6 is a direct regulator of breast CSC self-renewal [65] and IL-6/JAK2/STAT3 pathway is more active in CD44(+)CD24(-/low) breast cancer cells compared with other tumor cell types and its inhibition blocks the growth of xenografts [27].